World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
26239
World Ranking
17921
National Ranking
8939

Overview

Banu Arun is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research spans fields primarily related to biochemistry, genetics, molecular biology, and medicine. Within these domains, their work has a strong focus on genetics, oncology, cancer research, molecular biology, and pulmonary and respiratory medicine.

The scientist's research topics include:

  • BRCA gene mutations in cancer
  • Cancer Genomics and Diagnostics
  • PARP inhibition in cancer therapy
  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • DNA Repair Mechanisms
  • Cancer Treatment and Pharmacology

Banu Arun has contributed to several recent significant publications in the field, including:

  • Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses, 2020, Nature Genetics
  • Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial, 2020, The Lancet Oncology
  • Breast tumours maintain a reservoir of subclonal diversity during expansion, 2021, Nature
  • NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024, 2023, Journal of the National Comprehensive Cancer Network
  • Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes, 2020, Nature Genetics

They regularly collaborate with a number of researchers including Angelica M. Gutierrez-Barrera, Jennifer K. Litton, Debu Tripathy, Stacy L. Moulder, and Jason B. White.

Frequent publication venues for Banu Arun's work include:

  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • Annals of Oncology
  • Cancer

Banu Arun's research contributions align with a multidisciplinary approach intersecting genetics and oncology, emphasizing the genetic factors and molecular pathways involved in breast cancer and related cancers. Their work provides insights into genetic risk factors, targeted therapies such as PARP inhibitors, and cancer treatment strategies.

Best Publications

  • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

    Andrew Tutt;Mark Robson;Judy E Garber;Susan M Domchek

  • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer

    A Tutt;M Robson;J E Garber;S M Domchek

  • Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

    Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser

  • Association analysis identifies 65 new breast cancer risk loci

    Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley

  • PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression

    Shiping Jiao;Shiping Jiao;Weiya Xia;Hirohito Yamaguchi;Yongkun Wei

  • American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility

    Mark E. Robson;Mark E. Robson;Angela R. Bradbury;Banu K Arun;Susan M. Domchek

  • Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer

    Francisco J. Esteva;Vicente Valero;Daniel Booser;Laura T. Guerra

  • Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer

    Deann P. Atchley;Constance T. Albarracin;Adriana Lopez;Vicente Valero

  • Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

    Ana M. Gonzalez-Angulo;Kirsten M. Timms;Shuying Liu;Huiqin Chen

  • Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.

    M. Ayers;W.F. Symmans;J. Stec;A.I. Damokosh

  • Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

    Stig E. Bojesen;Stig E. Bojesen;Karen A. Pooley;Sharon E. Johnatty;Jonathan Beesley

  • Cancers Associated with BRCA1 and BRCA2 Mutations other than Breast and Ovarian

    Jacqueline Mersch;Michelle A. Jackson;Minjeong Park;Denise Nebgen

  • Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

    Timothy R. Rebbeck;Nandita Mitra;Fei Wan;Olga M. Sinilnikova

  • Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

    Roman Rouzier;Radhika Rajan;Peter Wagner;Kenneth R. Hess

  • Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

    Catherine M Phelan;Karoline B Kuchenbaecker;Karoline B Kuchenbaecker;Jonathan P Tyrer;Siddhartha P Kar

  • Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy

    Abenaa M. Brewster;Gabriel N. Hortobagyi;Kristine R. Broglio;Shu Wan Kau

  • American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction

    Kala Visvanathan;Rowan T. Chlebowski;Patricia Hurley;Nananda F. Col

  • Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

    Haoyu Zhang;Haoyu Zhang;Thomas U. Ahearn;Julie Lecarpentier;Daniel Barnes

  • Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk

    Fergus J. Couch;Xianshu Wang;Lesley McGuffog;Andrew Lee

  • Residual risk of breast cancer recurrence 5 years after adjuvant therapy

    Abenaa Brewster;Gabriel Hortobagyi;Kristine Broglio;Shu-Wan Kau

Frequent Co-Authors

Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Vicente Valero
Vicente Valero The University of Texas MD Anderson Cancer Center
Karen H. Lu
Karen H. Lu The University of Texas MD Anderson Cancer Center
Irene L. Andrulis
Irene L. Andrulis University of Toronto
Eitan Friedman
Eitan Friedman City University of New York
Anna Jakubowska
Anna Jakubowska Pomeranian Medical University
Judy Garber
Judy Garber Harvard University
Graham G. Giles
Graham G. Giles University of Melbourne
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a medical career, there are several related online degrees and career pathways worth exploring. Nursing is a popular option due to its demand and flexible entry points. Prospective nursing students often ask, what is the cheapest online college for nursing? Affordable programs can make pursuing this field more accessible, especially for those balancing work and study.

For those already in nursing, advancing your education is possible through online PhD programs in nursing, which open doors to research, teaching, and leadership roles. Another popular path is the RN to BSN track. There are several cheapest online BSN programs designed to help registered nurses earn their bachelor’s degree efficiently and affordably.

Additionally, individuals with non-nursing backgrounds can transition into the field via direct entry MSN programs for non nurses online. These innovative pathways allow career changers to enter nursing with a master’s degree in less time. Each pathway offers unique benefits, making it easier for students from various backgrounds to join and advance in healthcare.

Best Scientists Citing Banu Arun

Trending Scientists

Recently Published Articles